Until recently, MS clinical trial endpoints have focused primarily upon measures of disease activity instead of patient-reported outcome measures (PROMs). There is a growing desire, especially from regulatory authorities, to include endpoints measuring disease activity as seen from the patient’s perspective.
MS performance test
The Multiple Sclerosis Performance Test (MSPT) is a novel, iPad®-based disability assessment tool that resembles the Multiple Sclerosis Functional Composite (MSFC) [1,2]. It includes a computer-adapted version of Neuro-QoL, and 4 self-administered neuroperformance tests, providing measurements of walking speed, manual dexterity, low contrast visual acuity, and cognitive processing speed.
Convergent validity studies comparing the MSPT and MSFC subtests have been published  or are under editorial review. MSPT is being used as part of the international MS-PATHS network of MS centres, where over 40,000 ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« New Targets in Thymic Epithelial Tumours May Aid in Identifying Treatment Options Next Article
Nivolumab + Ipilimumab Safe First-line Treatment for NSCLC Patients with Comorbidities »
Table of Contents: ECTRIMS 2019
Towards a Comprehensive Assessment of MS Course
Monitoring and Treatment of Progressive MS
Optimising Long-Term Benefit of MS Treatment
Safety Assessment in the Post-Approval Phase
Pregnancy in the Treatment Era
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.